Last updated: May 22, 2026
Astellas v. Aurobindo (1:18-cv-00932): Litigation Summary, Claims at Issue, and Generic Entry Timeline Risk
Astellas Pharma Inc. v. Aurobindo Pharma Limited, No. 1:18-cv-00932, is a US Hatch-Waxman patent-infringement dispute brought in connection with Aurobindo’s proposed generic product. The case centers on whether Aurobindo’s ANDA would infringe specified Orange Book-listed patents (and whether any asserted patents are invalid or unenforceable). The litigation record determines the timing and leverage for any settlement-driven “at-risk” or authorized generic entry.
What patents were asserted in Astellas Pharma Inc. v. Aurobindo Pharma Limited (1:18-cv-00932)?
Core issue: infringement of Orange Book-listed patents covering Astellas’ reference drug and its protected claims (composition, formulation, and/or method-of-use). In Hatch-Waxman actions, the asserted patents are the ones identified in the NDA’s Orange Book listing and incorporated into the ANDA notice (Paragraph IV or other statutory notice type).
Which patent categories typically drive Astellas v. Aurobindo disputes
In Astellas generics-related disputes, the most common asserted sets include one or more of the following:
- Composition-of-matter or active ingredient analog coverage (broad claim scope; hard to design around).
- Formulation or dosage-form patents (narrower but can still block launch if claims read on the ANDA product design).
- Method-of-use / therapeutic regimen patents (can be harder for courts to treat as “not infringed” if the ANDA label and intended use map to the claims).
- Manufacturing/process patents (often tied to specific process parameters; infringement can turn on production comparables and expert evidence).
Litigation posture and legal theories
Hatch-Waxman infringement cases typically involve:
- Astellas: infringement and enforcement of validity.
- Aurobindo: invalidity (non-anticipation, non-obviousness, lack of written description, enablement, indefiniteness where raised), and unenforceability (inequitable conduct where pled).
Result impact: the outcome determines whether Aurobindo can launch immediately at the end of the statutory stay (if any) or only after expiration of the last asserted, uninvalidated patent.
How does 1:18-cv-00932 fit into the Hatch-Waxman Paragraph IV framework?
Featured-snippet answer: Paragraph IV litigation blocks ANDA approval/launch by triggering a statutory stay of FDA approval while the suit is pending, unless the FDA approves at-risk waivers or a final court outcome permits earlier launch.
Timeline mechanics that control generic entry
Key controls for settlement and entry risk include:
- ANDA filing and Paragraph IV notice date: starts the litigation clock and determines the initial FDA stay term.
- Court filing date (1:18-cv-00932): anchors when the statutory stay and briefing schedule begin in practical terms.
- Markman claim construction: often decisive for infringement/non-infringement.
- Claim/dispositives: summary judgment can narrow or eliminate infringement theories.
- Final judgment: determines whether Aurobindo can launch on patent expiry or whether further stays apply.
When does Astellas v. Aurobindo end exclusivity for the US generic?
Decision logic: exclusivity ends only when the last of the following is cleared:
- Expiration of the last asserted patent (if upheld).
- Final judgment invalidating the last asserted patent (if successful for Aurobindo).
- Settlement agreement that grants an earlier launch window or license.
Because the case number alone does not specify the reference product or asserted patent list in the prompt, a precise end-of-exclusivity date cannot be stated from the provided information.
What is the Orange Book status of Astellas’ drug in Astellas Pharma Inc. v. Aurobindo (1:18-cv-00932)?
Featured-snippet answer: The asserted patents are the ones listed in the Orange Book for the reference listed drug (RLD) and must be on the Orange Book for the Hatch-Waxman litigation to be procedurally grounded.
Orange Book listings that matter for litigation strategy
- List-by date and patent term: determine whether a design-around is feasible versus waiting for expiry.
- Exclusivity type (if any): application-specific exclusivities can compound patent barriers.
- Method-of-use vs. composition: affects whether label-carveouts or non-infringement arguments succeed.
Who are the key parties and what leverage each side typically has in this type of case?
Plaintiff
- Astellas Pharma Inc. (US brand or RLD rightsholder and Orange Book patent owner or exclusive license holder)
Defendant
- Aurobindo Pharma Limited (generic applicant proposing entry for the same therapeutic indication using an ANDA)
Typical leverage map
- Astellas leverage: patent estate breadth, early litigation posture, and ability to secure injunctive relief tied to unexpired patents.
- Aurobindo leverage: invalidity and non-infringement, plus settlement optionality if litigation risk is manageable.
How strong is the patent estate for Astellas’ RLD in this dispute?
Featured-snippet answer: Patent strength in Hatch-Waxman turns on (i) claim construction durability and (ii) whether prior art used in invalidity challenges is properly mapped to asserted limitations.
Strength indicators courts commonly weigh
- Claim scope breadth relative to the ANDA design.
- Whether the asserted claims survived earlier validity challenges (reexamination, PTAB, prior litigations).
- Obviousness record including the quality of expert testimony and prior-art teaching motivation.
- Written description/enablement issues tied to specific embodiments.
Outcome driver: if Aurobindo fails under claim construction, the case often shifts from validity to design-around licensing or settlement.
What claims does Aurobindo risk for non-infringement at launch?
In these disputes, non-infringement risk is assessed by:
- ANDAspecific label: method-of-use infringement often depends on intended use language.
- ANDA product composition/formulation: claim charts map excipients, particle size, polymorph, or delivery characteristics where relevant.
- Process comparability: if process claims exist, evidence from manufacturing records and expert analyses becomes central.
What procedural milestones usually determine outcomes in cases like 1:18-cv-00932?
Typical dispositive milestones include:
- Scheduling order and early claim construction.
- Markman hearing: defines infringement boundaries.
- Summary judgment on invalidity or non-infringement.
- Trial or consent judgment if not fully resolved.
Practical impact on business: each milestone narrows negotiation ranges for settlement and affects whether a party can credibly demand an earlier launch date.
Did the court issue a ruling, and how does it affect generic entry?
Featured-snippet answer: A court’s decision on infringement and validity controls whether Aurobindo can launch immediately or must wait for patent expiry. If the court invalidates asserted patents, entry can occur immediately after the statutory stay lifts. If the court finds infringement and validity, entry is enjoined until patent expiry.
However, the prompt provides only the case caption and docket number, not the judgment date or holdings, so litigation outcomes cannot be stated accurately.
Was there a settlement in Astellas v. Aurobindo (1:18-cv-00932)? What settlement terms usually matter?
Featured-snippet answer: Settlement terms usually govern launch timing, design-around requirements, and payment/royalty structures.
Common settlement dimensions in ANDA cases include:
- Agreed launch date (earlier than expiration or tied to partial patent invalidation).
- “Carve-out” patents: settlement can waive certain patents while reserving others.
- Design-around commitments: formulation or labeling changes to avoid specific claim coverage.
- Marketing limitations: delayed distribution, patient access restrictions, or exclusivity-scope constraints.
Without the settlement record, the specific settlement terms cannot be listed.
How does Astellas v. Aurobindo compare with other Astellas generic litigations?
In general, Astellas’ generic-focused litigations share a common risk profile:
- Early filing and Paragraph IV leverage: defendants often seek a narrow legal win to unlock launch.
- Settlement frequency: high in cases where claim construction could swing outcomes and where both sides face business pressure to control launch timing.
A product-specific comparison requires the asserted patent list and reference drug, which are not provided in the prompt.
What manufacturing or IP barriers could block Aurobindo even if patents fall?
Even if infringement or validity barriers are cleared, generic launch can be delayed by:
- FDA Chemistry, Manufacturing, and Controls (CMC) review for the ANDA.
- Bioequivalence (BE) study acceptance.
- Risk around specific polymorph/formulation parameters that impact stability and manufacturing reproducibility.
- Device or combination product components where approvals require separate approvals.
These factors can dominate the calendar even after patent resolution.
Key Case-Docket Facts (1:18-cv-00932)
| Item |
Data |
| Case |
Astellas Pharma Inc. v. Aurobindo Pharma Limited |
| Docket number |
1:18-cv-00932 |
| Jurisdiction (implied by US number formatting) |
US federal court (district-level docket) |
| Dispute type |
Hatch-Waxman patent infringement action tied to an ANDA |
| Parties |
Astellas Pharma Inc. (plaintiff) vs. Aurobindo Pharma Limited (defendant) |
| Business relevance |
Determines generic launch timing via patent validity/infringement outcomes and possible settlement |
Key Takeaways
- The litigation is a Hatch-Waxman-style patent dispute that determines whether Aurobindo can launch its ANDA product against Astellas’ reference drug before patent expiry.
- Case leverage typically shifts on claim construction, where infringement boundaries become fixed and validity arguments gain or lose practical traction.
- Launch timing is controlled by the last upheld asserted patent or by a settlement-triggered launch date, but specific dates and holdings are not provided in the input.
FAQs
- What typically triggers a statutory FDA stay in Paragraph IV cases like 1:18-cv-00932?
- How do label and “intended use” affect method-of-use patent infringement in ANDA cases?
- What claim construction issues most often decide infringement outcomes in formulation patent disputes?
- How do settlements in Hatch-Waxman cases translate into market entry dates for generics?
- What non-patent regulatory steps can still delay an ANDA launch after patent clearance?
References
- (No citable sources were provided in the prompt for the specific holdings, asserted patents, or procedural outcome in Astellas Pharma Inc. v. Aurobindo Pharma Limited, 1:18-cv-00932.)
